Business Overview: Simulations Plus, Inc. (NASDAQ: SLP)

---

Executive Summary

Simulations Plus, Inc. is a California-incorporated (1996) provider of modeling and simulation ("biosimulation") software and scientific consulting used across drug discovery, development, and commercialization. Its tools let pharmaceutical, biotech, and agrochemical companies predict how a drug compound will behave in the body — absorption, metabolism, toxicity — before running (or instead of running) certain costly animal and human studies, with the goal of shortening development timelines, lowering R&D costs, and supporting regulatory submissions.

Headquartered in Lancaster, California with additional offices in New York, North Carolina, Pennsylvania, and France, Simulations Plus is a small but well-established player sitting squarely inside the model-informed drug development (MIDD) niche alongside its much larger direct competitor, Certara. Fiscal 2025 revenue grew 13% to $79.2 million, continuing a long run of steady growth, though the year's reported results were overshadowed by a $77.2 million non-cash goodwill/intangible impairment tied to its 2024 acquisition of clinical-trial training company Pro-ficiency, which underperformed expectations and drove the company to a net loss despite healthy underlying cash profitability.

The company matters less for its size than for its position: its GastroPlus and ADMET Predictor software are referenced tools inside many real-world FDA and other regulatory drug submissions, giving Simulations Plus an outsized role relative to its revenue in how new drugs actually get approved.

---

1. Core Business Model & How They Work

Simulations Plus sells annually-licensed software and pairs it with scientific consulting, so that smaller clients without in-house expertise can still use its models correctly.

[ Mechanistic / AI-ML Models Built on Proprietary Data ] ➡️ [ Licensed Software (GastroPlus, ADMET Predictor, etc.) ]
                                                                        │
                                                                        ├──► Direct software license revenue (annual renewals)
                                                                        └──► Scientific consulting services (PBPK, QSP, clinical ops training)
                                                                                      │
                                                                                      ▼
                                                      [ Client's regulatory drug submission / development program ]

1. Software Licensing: Annually-renewed licenses for simulation and prediction software, generating recurring, high-margin revenue (58% of FY2025 revenue).
2. Consulting Services: Scientific staff apply the company's own models on a client's behalf — PKPD modeling, quantitative systems pharmacology (QSP), physiologically-based pharmacokinetic (PBPK) modeling, and clinical trial training — representing 42% of FY2025 revenue and a growing share.
3. Distribution: Primarily direct/internal sales, supplemented by independent distributors in Japan, China, India, South Korea, and Brazil, plus visibility from scientific conferences and publications.
4. Expansion Through Software Units: The company organizes its science into distinct product lines (discovery, development, clinical operations, and commercialization) and has periodically acquired adjacent capabilities, most notably clinical-trial training platform Pro-ficiency in 2024.

---

2. Business Segments

Simulations Plus reports two segments that map directly onto its license/services revenue split.

                     ┌───────────────────────────────┐
                     │   Simulations Plus, Inc.       │
                     └───────────────┬─────────────────┘
                                      │
                 ┌────────────────────┴────────────────────┐
                 ▼                                          ▼
      ┌───────────────────────┐                 ┌───────────────────────┐
      │       Software          │                 │       Services          │
      │   (~58% of revenue)     │                 │   (~42% of revenue)     │
      └───────────────────────┘                 └───────────────────────┘

Software (~58% of FY2025 revenue)

Licensed simulation, prediction, and modeling tools covering drug discovery through commercialization, sold on annual terms so revenue is largely recurring.

Services (~42% of FY2025 revenue)

Consulting engagements where the company's own scientists apply its software to a client's specific drug program, plus the newer clinical-trial training and medical-communications work added through the Pro-ficiency acquisition. This segment's revenue share has grown steadily (39% in FY2023, 41% in FY2024, 42% in FY2025).

---

3. Product Portfolio

---

4. Competitive Landscape

                    BREADTH OF PLATFORM
                Narrow / point-solution        Broad, end-to-end platform
             ┌───────────────────────────┬───────────────────────────────┐
  Mechanistic│   Metrum Research Group    │                                │
  Modeling   │   (consulting-led)         │          CERTARA               │
  Depth      │                            │   (broader M&A-built suite,    │
  (high)     │   SIMULATIONS PLUS         │    larger scale)               │
             │   (software + science-led  │                                │
             │    consulting)             │                                │
             ├───────────────────────────┼───────────────────────────────┤
  (lower)    │   Open-source tools,       │   ICON, WCG, Veeva             │
             │   in-house pharma teams    │   (CRO / clinical-data-        │
             │                            │    platform adjacent)          │
             └───────────────────────────┴───────────────────────────────┘

• Certara: The dominant direct competitor in model-informed drug development, significantly larger and built partly through acquisition; competes across nearly every product line Simulations Plus offers.
• Optibrium, Metrum Research Group: Smaller, more specialized competitors in ADMET prediction and PK/PD consulting, respectively.
• ICON, WCG, Veeva: Larger clinical research and data-platform companies that compete at the edges, particularly around clinical operations and trial support following the Pro-ficiency acquisition.
• Open-source tools and in-house pharma teams: A persistent competitive and pricing pressure, especially for smaller biotech clients with limited budgets.

Simulations Plus's stated differentiation is its proprietary experimental validation database, its scientific staff's domain expertise, and long-standing relationships with regulators (including the FDA) and academic institutions.

---

5. Strategic Strengths & Risks

Strengths (The Moat)

• Regulatory Embeddedness: GastroPlus and related tools are used inside real regulatory submissions; switching away risks disrupting a client's own interactions with the FDA and other regulators, a powerful form of switching cost.
• Proprietary Validation Data: Decades of experimental data used to calibrate and validate its mechanistic models are not easily replicated by a new entrant or open-source alternative.
• Recurring Revenue Base: Annual software licensing provides a predictable revenue core beneath the more variable consulting business.

Risks

• Pro-ficiency Impairment: The $77.2 million non-cash impairment in FY2025 shows integration/acquisition risk is real — the company's largest recent deal underperformed expectations.
• Scale Disadvantage vs. Certara: Its primary competitor is substantially larger, which could translate into greater R&D budgets and broader platform breadth over time.
• Customer Budget Sensitivity: Many clients are smaller biotech companies whose software and consulting budgets are sensitive to biotech funding cycles.
• Organizational Transition: The company restructured from a business-unit model to a function-based structure and shifted to account-based selling in Q4 FY2025 — execution risk during any such transition.

---

6. Financial Overview

---

7. Summary Conclusion

Simulations Plus occupies a durable, if small, niche: software and consulting that are genuinely embedded in how new drugs get discovered, tested, and approved, with a regulatory-grade validation history that is difficult for a new entrant or open-source project to match quickly. Its core software-and-services model continued growing through fiscal 2025, with underlying Adjusted EBITDA up 8%.

The headline risk is execution, not demand: the Pro-ficiency acquisition's large impairment is a reminder that growth-by-acquisition can misfire, and the company's much larger competitor, Certara, has more resources to invest in platform breadth. Whether Simulations Plus can keep its core biosimulation franchise growing while digesting the Pro-ficiency setback and a mid-2025 organizational restructuring is the key question for the business going forward.